Insights & news

European General Court Dismisses Medicines Dual Pricing Complaint Thus Allowing GSK To Avoid New Probe

  • 27/09/2018
  • Articles

The European General Court (“GC”) dismissed on 26 September 2018 a 1999 complaint filed by EAEPC, the industry association of parallel traders in medicines, that had urged the European Commission (the “Commission”) to resume its investigation of a “dual pricing” scheme operated by GlaxoSmithKline (“GSK”) in Spain. Under the scheme, the prices which GSK charged to wholesalers differed depending on whether the medicines were resold in Spain under regulated prices or were exported abroad free from pricing constraints.
 
GSK had been the subject of a Commission competition procedure which in 2009 had resulted in a verdict of the Court of Justice of the European Union (“ECJ”) that the dual pricing scheme had as its object the restriction of competition and thus infringed Article 101 (1), Treaty on the Functioning of the European Union (“TFEU”). The ECJ went on to declare that the Commission had not carried out a full examination of the arguments put forward by GSK in favour of an exemption of the scheme pursuant to Article 101 (3), TFEU.
 
Following the ECJ’s judgment, the Commission started its analysis of the scheme under Article 101 (3), TFEU and in 2012 also opened an investigation of alleged dual pricing practices in Spain by other firms. But in May 2014 the Commission decided to reject the 1999 complaint for lack of a sufficient Union interest in a continued investigation of the alleged competition law infringements. This is because (i) GSK’s conduct under scrutiny had ceased many years ago; (ii) that conduct did not produce enduring effects; and (iii) the case had been handled by national competition authorities and courts as well.
 
As noted, the EAEPC took steps to have the inquiry against GSK re-opened, but the GC has now confirmed the rejection of the complaint. EAEPC immediately indicated that it would consider filing an appeal to the ECJ.

Before the GC, the EAEPC challenged the Commission’s findings as inconclusive, questioned the absence of sufficient Union interest and characterised the reasoning underlying the decision as flawed.

In response, the GC considered that the EAEPC had failed to adduce evidence disproving the Commission’s findings.

It furthermore noted that the Commission had broad discretion in determining a matter to be in the Union interest. While the case may bear a “special feature” due to a Commission decision that was subject to two European judgments adopted by the ECJ and the GC, the GC noted that the ‘special feature’ evoked by EAEPC does not prevent the Commission from concluding that there is no sufficient Union interest based on the Commission’s three considerations cited earlier.

By the same token, the GC also rejected EAEPC’s position that the Commission failed to examine and state reasons for its conclusion, as the Commission’s decision clearly indicates that the disputed dual pricing scheme had been suspended and that GSK had refrained from implementing it.

Lastly, the GC stressed that the rejection of the complaint was not tantamount to an authorisation of export restrictions in Spain. It supported the Commission’s position that “the fact of not adopting a decision on an infringement cannot in itself be determinative of the self-assessment carried out by the undertakings under Article 101 (3), TFEU”. The GC specified that self-assessment should be based on current market conditions and not on a decision rejecting a complaint for lack of Union interest in a specific historical context.

The ECJ’s judgment is available at this link.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 28/11/2019
    • Articles

    European Commission Publishes State of Health in EU 2019 and Makes Policy Recommendations for Affordable Medicines

    The European Commission published today its Companion Report on the State of Health in the EU 2019 (see, attached – the “Report”) which forms the culmination of a cycle started in 2016 to develop expertise on performance assessments of the health systems in the Member States. The Report accordingly offers a number of general assessments of policy issues such as the decline in vaccination confidence, the digital transformation of health promotion and disease prevention and the requisite holistic approach in the quest for safe, effective and affordable medication. In addition, the Report also publishes key health findings for each of the 28 Member States. In a chapter entitled “Breaking down silos for safe, effective and affordable medicines”, the Report identifies four areas for Member States to focus on: • Building up Member State capacity to assess the value of medical technology – According to the Report, this implies greater cooperation among Member States, as this will bridge the information gap with suppliers. One channel for cooperation would be created by the proposed Health Technology Assessment Regulation which is currently under review by the EU political institutions. • Pooling knowledge and expertise regarding medicine pricing and procurement – The Report favours additional cooperation among and with the national competition authorities that built up expertise on excessive pricing cases and also maps the various forms of governmental cooperation on medicine procurement such as the Beneluxa and Valetta initiatives. • Maximising cost savings from generics and biosimilars – The Report notes that the uptake of these product categories is still unevenly spread across the EU. • Using medicines appropriately in hospitals – The Report calls for an update of best practices that date back to 2010.

    Read more
    • 26/11/2019
    • Articles

    EU Health Ministers to Consider Policies Fostering Cooperation to Improve Access to Medicines and Reduce Medicine Shortages

    The Finnish Presidency of the European Council has invited Member States to a policy debate that will consider avenues towards strengthened cooperation in order to improve access to medicines (see, attached note of 22 November 2019 – the “Note”). The debate should take place during the employment, social policy, health and consumer affairs Council of 9 December 2019. The Note takes stock of the many initiatives that have been taken in recent years at various levels of government and on a wide range of subjects. At the same time, guided by what it describes as the “four phases of a medicine’s lifecycle”, the Note also identifies a number of possible regulatory gaps. It specifically welcomes Member State comments on the requirement to maintain medicines on the market, reduce “uncontrolled market withdrawals” and curb shortages. On this basis, it requests the Member States to take a position on the following issues: 1. Concrete measures to be taken by both Member States and the European Commission to ensure access to medicines and avoid medicine shortages. 2. Possible EU rules to (i) make EU-based back-up manufacturing capacity mandatory; (ii) create earlier warnings of supply interruptions; and (iii) ensure continuity of supply. 3. Strengthened Member State cooperation in areas as diverse as sustainability of budgets and shortages of medicines. While a parting shot for the Finnish Presidency of the Council (In 2020, first Croatia and then Germany will succeed Finland), the Note sets the tone for an ambitious medicines policy to be adopted by the new European Commission which is now expected to become operational on 1 December 2019.

    Read more
    • 22/11/2019
    • Articles

    Spanish Competition Authority Accuses Merck Sharp & Dohme of Abuse of Intellectual Property Rights to Delay Third-Party Market Entry

    On 21 November 2019, the Spanish competition authority, the "Comisión Nacional de los Mercados y la Competencia ("CNMC"), showed once again its determination to crack down on anticompetitive practices in the pharmaceutical sector when it announced the start of competition proceedings against Merck Sharp & Dohme S.A. and its European parent company MSD Human Health Holding B.V. (together MSD) (see, attached press release). MSD stands accused of having abused its intellectual property rights, through court action and otherwise, in hopes of delaying third-party entry on the Spanish market for combined hormonal contraceptive medicines of the vaginal ring type. MSD may thus have breached Article 102 of the Treaty on the Functioning of the European Union as well as its Spanish counterpart, namely Article 2 of Law 15/2007 of 3 July 2007 on the Protection of Competition. The CNMC has been quick in reaching its tentative conclusion as on premise inspections in this case took place as recently as May 2019 (see, Van Bael & Bellis Life Sciences Newsflash of 27 May 2019).

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *